By Frank Prenesti
Date: Wednesday 05 Jan 2022
LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
The deal gives Cabaletta a non-exclusive licence for LentiVector to be used on Chimeric autoantibody receptor T programme, DSG3-CAART, for autoimmune disease.
No financial details were revealed, but Oxford Biomendica said the arrangements of the LSA were "in line with comparable deals the group has previously secured".
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 412.50p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 445.00p |
52 Week Low | 166.80p |
Volume | 127,284 |
Shares Issued | 105.92m |
Market Cap | £436.93m |
Beta | 1.21 |
RiskGrade | 125 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 3 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 0 |
Total | 9 |
No dividends found |
Time | Volume / Share Price |
16:29 | 21 @ 413.50p |
16:29 | 444 @ 413.50p |
16:26 | 850 @ 412.60p |
16:21 | 42 @ 413.50p |
16:21 | 1,000 @ 413.00p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research